CN Patent

CN103288833B — 作为激酶抑制剂的咪唑并三嗪和咪唑并嘧啶

Assigned to Because of C1-esteraseremmer-N parent corporation · Expires 2018-01-12 · 8y expired

What this patent protects

本发明为作为激酶抑制剂的咪唑并三嗪和咪唑并嘧啶，涉及为诸如c‑Met的激酶抑制剂并用于治疗癌症和与激酶途径失调有关的其它疾病的咪唑并[1,2‑b][1,2,4]三嗪和咪唑并[1,2‑a]嘧啶，及其药用组合物。

USPTO Abstract

本发明为作为激酶抑制剂的咪唑并三嗪和咪唑并嘧啶，涉及为诸如c‑Met的激酶抑制剂并用于治疗癌症和与激酶途径失调有关的其它疾病的咪唑并[1,2‑b][1,2,4]三嗪和咪唑并[1,2‑a]嘧啶，及其药用组合物。

Drugs covered by this patent

capmatinib-hydrochloride (CAPMATINIB HYDROCHLORIDE)

Patent Metadata

Patent number: CN103288833B
Jurisdiction: CN
Classification: —
Expires: 2018-01-12
Drug substance claim: No
Drug product claim: No
Assignee: Because of C1-esteraseremmer-N parent corporation
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.